The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans and is often treated with a CPAP machine, but is often declined due to its cumbersome nature.

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow | After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound,

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs Zepbound and Mounjaro. The lawsuit, filed by compounding pharmacies, aims to reverse the FDA's determination that these drugs are no longer in short supply.

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.64% and currently trading at $772.95. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss of about 20%, compared to more than 13% for the rival medicine. Lilly and Novo Nordisk both are leaders in this market today.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive signals” are emerging when it comes to the consistent supply of GLP-1 medicines for diabetes and weight loss, Bill Coyle, global head of biopharma at ZS, said in a recent interview.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over